Who is sponsoring NCT02731378?

NCT02731378 is sponsored by Shanghai East Hospital.

What drugs are being tested in NCT02731378?

Interventions in NCT02731378: Erythropoietins (EPO), Aggressive iron dextran supplementation, Erythropoietins (EPO), Sustained iron dextran supplementation.

What condition does NCT02731378 study?

NCT02731378 studies Chemotherapy-induced Anaemia.

Is NCT02731378 still recruiting?

NCT02731378 is currently status unknown. Last updated 28 October 2016.

Last reviewed 2016-10-28 · How we verify

NCT02731378

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combination With Intravenous Iron Supplementation or Doubling Erythropoietin Dose for Patients With Chemotherapy-induced Anaemia Inadequately Responsive to Initial Erythropoietin Treatment Alone

Status unknown Phase 4 Last updated 28 October 2016

What this trial tests

Phase 4 trial testing Erythropoietins (EPO) in Chemotherapy-induced Anaemia in 603 participants. Status unknown.

Timeline

1 December 2016

Primary endpoint
1 April 2019

1 November 2019

Quick facts

Lead sponsor	Shanghai East Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	603
Start date	1 December 2016
Primary completion	1 April 2019
Estimated completion	1 November 2019
Sites	6 locations across China

Drugs / interventions tested

Erythropoietins (EPO) — full drug profile →
Aggressive iron dextran supplementation — full drug profile →
Erythropoietins (EPO) — full drug profile →
Sustained iron dextran supplementation — full drug profile →

Conditions studied

Chemotherapy-induced Anaemia — all drugs for Chemotherapy-induced Anaemia →

Sponsor

Shanghai East Hospital

Who can join

18 and older, any sex, with Chemotherapy-induced Anaemia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Hb response rate
Time frame: up to week 15
A CIA patient would be defined as an Hb responder to study treatment if either Hb concentration of this patient is at least 12 g/dL or there is an increase in Hb levels of more than 2-g/dL compared to baseline level without blood transfusions initiated in the previous 28 days.

Sponsor's own description

A multicentre, randomized, open-label, parallel-group, active controlled non-inferiority study

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta-analysis.
Adams A, Scheckel B, Habsaoui A, Haque M, et al · · 2022 · cited 7× · PMID 35724934 · DOI 10.1002/14651858.cd012633.pub2
Combination with intravenous iron supplementation or doubling erythropoietin dose for patients with chemotherapy-induced anaemia inadequately responsive to initial erythropoietin treatment alone: study protocol for a randomised controlled trial.
Chen L, Jiang H, Gao W, Tu Y, et al · · 2016 · cited 1× · PMID 27855097 · DOI 10.1136/bmjopen-2016-012231

Verify or expand the search:

Other Shanghai East Hospital trials

Trials by the same sponsor.

NCT07519161 — Pharmacological Intervention to Prevent NOAF After TAVR · NA · not yet recruiting
NCT07516223 — MRI-Assisted Guidance for Non-Essential Tissue Sampling · NA · not yet recruiting
NCT07279259 — Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management · Phase 2 · recruiting
NCT07294495 — Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Tr · NA · not yet recruiting
NCT07290816 — Effect of Non-invasive Neuromodulation on the Quality of Intestinal Cleansing · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02731378 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai East Hospital
Last refreshed: 28 October 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02731378.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing